Yahong Pharmaceuticals (688176.SH): Clinical trial application for APL-2302 has been approved by the National Medical Products Administration.

Yahong Pharmaceuticals (688176.SH) announced that it has recently received the "Notice of Approval for Clinical Trials of Drugs" issued by the National Medical Products Administration (NMPA). The company's independently developed APL2302 (ASN-3186 capsule) has been granted approval for clinical trials by the NMPA, and it plans to conduct clinical trials for advanced solid tumors. The approval for the APL-2302 clinical trial application by the NMPA will not have a significant impact on the company's recent performance. Due to the long research and development cycle, multiple approval processes, and large research and development investments involved in drug development, it is susceptible to uncertainties. Investors are advised to make decisions cautiously and be aware of investment risks.